Contemporary Clinical Trials – Volume 41, In Progress (March 2015)

Contemporary Clinical Trials
Volume 41, In Progress (March 2015)

Immunogenicity and safety of measles–mumps–rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: A randomized non-inferiority study
Original Research Article
Pages 1-8
Reinaldo de Menezes Martins, Birute Curran, Maria de Lourdes Sousa Maia, Maria das Graças Tavares Ribeiro, Luiz Antonio Bastos Camacho, Marcos da Silva Freire, Anna Maya Yoshida Yamamura, Marilda Mendonça Siqueira, Maria Cristina F. Lemos, Elizabeth Maciel de Albuquerque, Vanessa dos Reis von Doellinger, Akira Homma, Laura Saganic, Courtney Jarrahian, Michael Royals, Darin Zehrung
This study aimed to determine if immunogenicity to measles–mumps–rubella vaccine delivered to infants via a disposable-syringe jet injector (DSJI) was non-inferior to that administered by needle and syringe (NS). Vaccination safety was evaluated, as were the use, performance, and acceptability of each delivery method. The DSJI was the PharmaJet® 2009 generation-1 device (G1) and the vaccine was measles–mumps–rubella vaccine from Bio-Manguinhos. Five hundred eighty-two healthy Brazilian infants were randomized to receive vaccine via G1 or NS. Seroconversion rates against measles and mumps viruses in the G1 treatment group did not meet non-inferiority criteria when compared with the NS group; however, responses in the G1 group to rubella virus were non-inferior to those of NS vaccinees. Most adverse events were mild or moderate. Crying after injection was more frequent in the NS group, and local skin reactions were more common in the G1 group. Five serious adverse events were judged causally unrelated to treatment and all resolved. Parents/guardians expressed a strong preference for G1 over NS for their children. Vaccinators found the G1 easy to use but noted incomplete vaccine delivery in some cases. Although the G1 has been superseded by an updated device, our results are important for the continued improvement and evaluation of DSJIs, which have the potential to overcome many of the challenges and risks associated with needle-based injections worldwide. Recommendations for future DSJI clinical studies include rigorous training of vaccinators, quantitative measurement of wetness on the skin following injection, and regular monitoring of device and vaccinator performance.